1,217
Participants
Start Date
August 31, 2007
Primary Completion Date
September 30, 2010
Study Completion Date
July 31, 2011
ranibizumab
Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
aflibercept injection (VEGF Trap-Eye, BAY86-5321)
Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
New York
New York
New York
Brooklyn
Lynbrook
Slingerlands
Albany
Poughkeepsie
Syracuse
Rochester
Rochester
West Mifflin
Pittsburgh
Pittsburgh
Pittsberg
Kingston
Philadelphia
Philadelphia
Philadelphia
Wyomissing
Chevy Chase
Towson
Baltimore
Baltimore
Hagerstown
Fairfax
Charlottesville
Richmond
Winston-Salem
Raleigh
Charlotte
Southern Pines
Asheville
West Columbia
Columbia
Charleston
Greenville
Augusta
Jacksonville
Pensacola
Gainesville
Altamonte Springs
Mt. Dora
Orlando
Orlando
Miami
Miami
Fort Lauderdale
Palm Beach Gardens
Boynton Beach
Tampa
Winter Haven
Fort Myers
Fort Myers
Oscala
Stuart
Birmingham
Birmingham
Nashville
Memphis
Memphis
Louisville
Louisville
Paducah
Columbus
Toledo
Cincinnati
Cincinnati
Indianapolis
Indianapolis
Indianapolis
Fort Wayne
New Albany
Southfield
Royal Oak
Ann Arbor
Detroit
West Bloomfield
Battle Creek
Jackson
Grand Rapids
Milwaukee
Madison
Minneapolis
Edina
Rochester
Rapid City
Madison
Missoula
Oak Brook
Florissant
St Louis
Kansas City
Kansas City
Springfield
Wichita
Omaha
Lincoln
New Orleans
New Orleans
Shreveport
Oklahoma City
DeSoto
Dallas
Fort Worth
Fort Worth
Houston
Galveston
San Antonio
Corpus Cristi
McAllen
Austin
Abilene
Odessa
Aurora
Denver
Denver
Salt Lake City
Salt Lake City
Phoenix
Phoenix
Tucson
Tucson
Albuquerque
Las Vegas
Los Angeles
Los Angeles
Beverly Hills
Torrance
Pasadena
Glendale
Westlake Village
La Jolla
Poway
San Diego
Palm Springs
Loma Linda
Irvine
Santa Ana
Fullerton
Yorba Linda
Ventura
Menlo Park
Mountain View
San Francisco
Oakland
Campbell
Sacramento
‘Aiea
Honolulu
Portland
Portland
Salem
Ashland
Seattle
Silverdale
Bridgeport
Hamden
New Haven
New London
Sarasota
Boston
Iowa City
Bangor
Portland
Boston
Boston
Boston
Peabody
Lawrenceville
New Brunswick
Northfield
Teaneck
Toms River
Providence
Burlington
Calgary
Vancouver
Victoria
Halifax
London
Mississauga
Ottawa
Toronto
Toronto
Montreal
Montreal
Regina
Collaborators (1)
Bayer
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY